Mohammed Khalid Pasha
Mohammed Khalid Pasha
Lee Kong Chian School of Medicine- Imperial college London-NTU
Verified email at
Cited by
Cited by
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview …
SNR Pasha MK, Muzeeb S, Basha SJ, Shashikumar D
Biomed Chromatogr 20 (3), 282-293, 2006
Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5, 7, 26-triaza-tetracyclo [19.3. 1.1 (2, 6). 1 (8, 12)] heptacosa-1 (25), 2 (26), 3, 5, 8, 10, 12 (27 …
AD William, ACH Lee, S Blanchard, A Poulsen, EL Teo, H Nagaraj, E Tan, ...
Journal of medicinal chemistry 54 (13), 4638-4658, 2011
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
V Novotny-Diermayr, S Hart, KC Goh, A Cheong, LC Ong, H Hentze, ...
Blood Cancer Journal 2 (5), e69, 2012
VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
S Hart, V Novotny-Diermayr, KC Goh, M Williams, YC Tan, LC Ong, ...
Molecular cancer therapeutics, 2012
Discovery of Kinase Spectrum Selective Macrocycle (16 E)-14-Methyl-20-oxa-5, 7, 14, 26-tetraazatetracyclo [19.3. 1.1 (2, 6). 1 (8, 12)] heptacosa-1 (25), 2 (26), 3, 5, 8 (27 …
AD William, ACH Lee, KC Goh, S Blanchard, A Poulsen, EL Teo, ...
Journal of Medicinal Chemistry 55 (1), 169-196, 2011
Discovery of the Macrocycle (9 E)-15-(2-(Pyrrolidin-1-yl) ethoxy)-7, 12, 25-trioxa-19, 21, 24-triaza-tetracyclo [18.3. 1.1 (2, 5). 1 (14, 18)] hexacosa-1 (24), 2, 4, 9, 14 (26 …
AD William, ACH Lee, A Poulsen, KC Goh, B Madan, S Hart, E Tan, ...
Journal of Medicinal Chemistry 55 (6), 2623-2640, 2012
In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species
PR Venkatesh, E Goh, P Zeng, LS New, L Xin, MK Pasha, ...
Biological and Pharmaceutical Bulletin 30 (5), 1021-1024, 2007
Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics
R Jayaraman, VP Reddy, MK Pasha, H Wang, K Sangthongpitag, P Yeo, ...
Drug metabolism and disposition 39 (12), 2219-2232, 2011
Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue
V Novotny-Diermayr, N Sausgruber, YK Loh, MK Pasha, R Jayaraman, ...
Molecular Cancer Therapeutics 10 (7), 1207-1217, 2011
Forskolin: Genotoxicity assessment in Allium cepa
KP Mohammed, A Aarey, S Tamkeen, P Jahan
Mutation Research/Genetic Toxicology and Environmental Mutagenesis 777, 29-32, 2015
Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats
S Muzeeb, MK Pasha, SJS Basha, R Mullangi, NR Srinivas
Xenobiotica 35 (8), 825-838, 2005
Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
MK Pasha, R Jayaraman, VP Reddy, P Yeo, E Goh, A Williams, KC Goh, ...
2-Anilino-4-aryl-8< i> H</i>-purine derivatives as inhibitors of PDK1
S Blanchard, CK Soh, CP Lee, A Poulsen, Z Bonday, KL Goh, KC Goh, ...
Bioorganic & medicinal chemistry letters, 2012
Metabolism and disposition of pacritinib (SB1518), an orally active Janus Kinase 2 inhibitor in preclinical species and humans
R Jayaraman, MK Pasha, A Williams, K Cee Goh, K Ethirajulu
Drug Metabolism Letters 9 (1), 28-47, 2015
Pharmacokinetic/Pharmacodynamic (PK/PD) relationships of novel HDAC inhibitors in an HCT-116 mouse xenograft tumor model
R Jayaraman, M Khalid Pasha, P Yeo, K Sangthongpitag, H Wang, ...
AACR, 2009
Salt forms of amino pyrazine purine based selective kinase inhibitor
Discovery of SB1317: A novel small molecule macrocycle with a unique kinase inhibitory spectrum in phase 1 clinical trials for hematological malignancies
A William, S Blanchard, A Lee, A Poulsen, E Sun, EL Teo, H Nagaraj, ...
Cancer Research 71 (8 Supplement), 3591-3591, 2011
Design, synthesis and SAR studies leading to SB1518, a novel macrocyclic JAK2/FLT3 inhibitor in phase 2 clinical trials for myelofibrosis and lymphoma
A Lee, A William, A Poulsen, E Tan, H Nagaraj, KL Goh, WC Ong, KC Goh, ...
Cancer Research 71 (8 Supplement), 3564-3564, 2011
The histone deacetylase inhibitor SB939 acts synergistically with Sorafenib in an orthotopic model of hepatucellular carcinoma
V Novotny-Diermayr, K Sangthongpitag, MK Goh, YK Loh, LC Ong, ...
Cancer Research 70 (8 Supplement), 5436-5436, 2010
Novel potent and selective mTOR/PI3K inhibitors that inhibit tumor growth in animal models through efficient sustained shut down of the PI3K/Akt signaling pathway
Z Bonday, M Williams, H Nagaraj, A Poulsen, H Hentze, DZ Chen, ...
The system can't perform the operation now. Try again later.
Articles 1–20